All In Biotech

Drug Trial Radar · NCT06079372

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

A Phase 3, Randomized, Open-label, Parallel-arm, Active-controlled, Multicenter Study to Evaluate Safety and Efficacy of ALXN1850 Versus Asfotase Alfa Administered Subcutaneously in Pediatric Participants (2 to < 12 Years of Age) With Hypophosphatasia (HPP) Previously Treated With Asfotase Alfa

Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

43

Actual

Start

Apr 2, 2024

Primary completion

Jul 23, 2025

Study completion Feb 29, 2028

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the safety and tolerability of ALXN1850 versus asfotase alfa in pediatric participants with HPP previously treated with asfotase alfa.

Conditions

  • Hypophosphatasia

Interventions

  • ALXN1850Drug

    ALXN1850 will be administered via subcutaneous (SC) injection.

  • asfotase alfaDrug

    Asfotase alfa will be administered via SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline Through Day 169

Locations

21 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Hartford, Connecticut

  • Research Site

    Baltimore, Maryland

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Kansas City, Missouri

  • Research Site

    Durham, North Carolina

  • Research Site

    Nashville, Tennessee

  • Research Site

    Mar del Plata, Argentina

  • Research Site

    South Brisbane, Australia

  • Research Site

    Ottawa, Ontario, Canada

  • Research Site

    Bunkyō City, Japan

  • Research Site

    Minatoku, Japan

  • Research Site

    Suita-shi, Japan

  • Research Site

    Yonago-shi, Japan

  • Research Site

    Altındağ, Turkey (Türkiye)

  • Research Site

    Ankara, Turkey (Türkiye)

  • Research Site

    Edirne, Turkey (Türkiye)

  • Research Site

    Erzurum, Turkey (Türkiye)

  • Research Site

    Istanbul, Turkey (Türkiye)

  • Research Site

    Birmingham, United Kingdom

  • Research Site

    Manchester, United Kingdom

  • Research Site

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.